Bristol-Myers Squibb Company BMY NYSE

Bristol-Myers Squibb Company (BMY) reported total assets of $90.04B and total liabilities of $71.53B for fiscal year 2025, resulting in total equity of $18.51B.

The company held $10.67B in cash and short-term investments. Total debt stood at $47.14B, with net debt of $36.93B. The Debt-to-Equity (D/E) ratio was 2.55 (leveraged).

Current ratio is 1.26, suggesting adequate short-term liquidity. Interest coverage is 8.4x (strong).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (75/100) — Total assets $90.04B and equity $18.51B support the company's competitive scale
• VALUE (69/100) — Debt-to-Equity 2.55 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%

MRK

Merck & Co., Inc.

$119.96

-0.16%

AMGN

Amgen Inc.

$350.95

+0.32%

GILD

Gilead Sciences, Inc.

$140.45

+1.02%

PFE

Pfizer Inc.

$27.13

-0.77%

GSK

GSK plc

$59.18

+0.41%